Quantifying Variation in Treatment Utilization for Type 2 Diabetes Across Five Major University of California Health Systems
Open Access
- 2 February 2021
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (4), 908-914
- https://doi.org/10.2337/dc20-0344
Abstract
OBJECTIVE: Using the newly created University of California (UC) Health Data Warehouse, we present the first study to analyze antihyperglycemic treatment utilization across the five large UC academic health systems (Davis, Irvine, Los Angeles, San Diego, and San Francisco). RESEARCH DESIGN AND METHODS: This retrospective analysis used deidentified electronic health records (EHRs; 2014–2019) including 97,231 patients with type 2 diabetes from 1,003 UC-affiliated clinical settings. Significant differences between health systems and individual providers were identified using binomial probabilities with cohort matching. RESULTS: Our analysis reveals statistically different treatment utilization patterns not only between health systems but also among individual providers within health systems. We identified 21 differences among health systems and 29 differences among individual providers within these health systems, with respect to treatment intensifications within existing guidelines on top of either metformin monotherapy or dual therapy with metformin and a sulfonylurea. Next, we identified variation for medications within the same class (e.g., glipizide vs. glyburide among sulfonylureas), with 33 differences among health systems and 86 among individual providers. Finally, we identified 2 health systems and 55 individual providers who more frequently used medications with known cardioprotective benefits for patients with high cardiovascular disease risk, but also 1 health system and 8 providers who prescribed such medications less frequently for these patients. CONCLUSIONS: Our study used cohort-matching techniques to highlight real-world variation in care between health systems and individual providers. This demonstrates the power of EHRs to quantify differences in treatment utilization, a necessary step toward standardizing precision care for large populations.Funding Information
- National Institute of General Medical Sciences (R01 GM079719)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK098722, R01 DK112304)
- National Heart, Lung, and Blood Institute (K23 HL136899)
- National Center for Advancing Translational Sciences (UL1 TR001872)
This publication has 43 references indexed in Scilit:
- Risk for End-Stage Renal Disease Over 25 Years in the Population-Based WESDR CohortDiabetes Care, 2014
- ForewordKidney International Supplements, 2012
- Competing risks in epidemiology: possibilities and pitfallsInternational Journal of Epidemiology, 2012
- The Danish National Patient RegisterScandinavian Journal of Public Health, 2011
- The Danish Register of Causes of DeathScandinavian Journal of Public Health, 2011
- Cumulative Risk, Age at Onset, and Sex-Specific Differences for Developing End-Stage Renal Disease in Young Patients With Type 1 DiabetesDiabetes, 2010
- Competing Risk of Death: An Important Consideration in Studies of Older AdultsJournal of the American Geriatrics Society, 2010
- Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelinesBMC Medical Research Methodology, 2009
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008
- Unbiased Recursive Partitioning: A Conditional Inference FrameworkJournal of Computational and Graphical Statistics, 2006